Avalo Therapeutics (AVTX) Current Deferred Revenue (2022 - 2023)
Avalo Therapeutics' (AVTX) quarterly Current Deferred Revenue came in at $111000.0 in Q1 2023, up 26.14% on a QoQ basis from $88000.0 in Q4 2022.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Current Deferred Revenue (2022 - 2023) Analysis & Trends
Avalo Therapeutics (AVTX) has 2 years of Current Deferred Revenue data on file, last reported at $111000.0 in Q1 2023.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $111000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $111000.0 (changed N/A YoY) and the FY2022 annual result came in at $88000.0, changed N/A from the prior year.
- Current Deferred Revenue rose to $111000.0 in Q1 2023, from $88000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $442000.0 in Q3 2022 to a low of $88000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 111,000.00 |
| Dec 31, 2022 | 88,000.00 |
| Sep 30, 2022 | 442,000.00 |